Monthly Newsletter

Synexus, the world's largest company responsible for the recruitment and running of clinical trials, has won its first contract to conduct ophthalmology studies. The Manchester-based company announced its intention to become involved in ophthalmology trials last October, following discussions with leading sponsors

The trial, conducted on behalf of a leading pharmaceutical company, will be carried out across several of Synexus' 26 Dedicated Research Centres, with recruitment already underway.

Chief Executive of Synexus, Dr Christophe Berthoux, is delighted with these significant new business wins: "We have worked hard to secure the right expertise to support our developments in the ophthalmology field and also to invest in the best technology to support the trials sponsors are looking to undertake. It is further testimony to our reputation, gained in other therapeutic areas, particularly in terms of rapid recruitment, that these sponsors have come to us to deliver their studies for ocular drug development.

Synexus has recently announced its intention to establish a presence in the US. The company is now enjoying the support of more leading sponsors including pharmaceutical organisations and major CROs for its model that recruits high numbers of patients to a limited number of sites.

About Synexus

Synexus® headquartered in Manchester, England, is the world's largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients.  Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.

The traditional way of recruiting for clinical trials through individual doctors is still by far the most common method, despite the fact that each doctor only recruits an average of five patients per study and more than 60 percent recruit one or less.  This incredibly costly model remains the norm.